Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a diabetes drug boost weight loss after bypass surgery?

NCT ID NCT06162715

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This pilot trial tests whether tirzepatide, a drug used for diabetes and weight loss, can help people who still have obesity one year after gastric bypass surgery. Thirty participants will either receive the drug or standard care. The study tracks weight changes and any stomach-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tirzepatide (also known as Zepbound or Mounjaro)
What this could lead to
If it works, this could offer a new option for people who still have obesity after gastric bypass surgery, helping them lose more weight.
What could go wrong
This is a small pilot study with only 30 people, so results may not apply to everyone. Side effects like gastrointestinal symptoms are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject must be able to understand and provide informed consent. 2. BMI \> 30 12 months after bariatric surgery. 3. Age \> 25 and \< 65 4. Patients undergoing primary Roux-en-Y Gastric Bypass Exclusion Criteria: 1. Inability or unwillingness of a subject to give written informed consent or comply with the study protocol. 2. Diagnosis of type I Diabetes 3. Revisional bariatric surgery (prior adjustable gastric band, sleeve gastric, vertical banded gastroplasty). 4. Use of medications for type 2 di 5. Hemoglobin A1c \> 8.5 in last 3 months. 6. Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months As this would preclude patients from undergoing bariatric surgery. 7. Personal history of pancreatitis as determined by history. 8. Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2 9. Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period. 10. Use of systemic glucocorticoids in the past 28 days 11. Myocardial infarction, unstable angina, stroke, or heart failure (NYHA class II) within 1 year by history. 12. History of solid organ transplant. 13. History of physician-diagnosed malignancy (other than excised non-melanoma skin cancer) in the past 5 years. 14. Current uncontrolled hypertension (systolic \>150, diastolic \>90) or untreated hyperthyroidism. 15. Current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements. 16. Screening creatinine elevation with EGFR \< 60 at time of randomization. 17. Tobacco use in last 12 months 18. Pregnancy 19. Prisoners 20. Unable or unwilling to follow-up 21. Unable to understand English/Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bmi greater than 30 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.